Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with
cirrhosis ascites who fail to response adequately to treatment with common diuretics.